- Home
- KBDC vs MYGN Comparison
KBDC vs MYGN Comparison
Compare KBDC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- MYGN
- Stock Information
- Founded
- KBDC 2021
- MYGN 1991
- Country
- KBDC United States
- MYGN United States
- Employees
- KBDC N/A
- MYGN N/A
- Industry
- KBDC
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KBDC
- MYGN Health Care
- Exchange
- KBDC Nasdaq
- MYGN Nasdaq
- Market Cap
- KBDC 1.2B
- MYGN 744.7M
- IPO Year
- KBDC N/A
- MYGN 1995
- Fundamental
- Price
- KBDC $15.65
- MYGN $4.03
- Analyst Decision
- KBDC Buy
- MYGN Hold
- Analyst Count
- KBDC 5
- MYGN 16
- Target Price
- KBDC $16.60
- MYGN $16.63
- AVG Volume (30 Days)
- KBDC 166.0K
- MYGN 2.8M
- Earning Date
- KBDC 05-12-2025
- MYGN 05-06-2025
- Dividend Yield
- KBDC 9.59%
- MYGN N/A
- EPS Growth
- KBDC N/A
- MYGN N/A
- EPS
- KBDC N/A
- MYGN N/A
- Revenue
- KBDC N/A
- MYGN $831,300,000.00
- Revenue This Year
- KBDC $193.84
- MYGN $2.96
- Revenue Next Year
- KBDC $13.81
- MYGN $8.36
- P/E Ratio
- KBDC N/A
- MYGN N/A
- Revenue Growth
- KBDC N/A
- MYGN 7.38
- 52 Week Low
- KBDC $13.93
- MYGN $3.98
- 52 Week High
- KBDC $17.99
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KBDC N/A
- MYGN 17.69
- Support Level
- KBDC N/A
- MYGN $6.94
- Resistance Level
- KBDC N/A
- MYGN $7.81
- Average True Range (ATR)
- KBDC 0.00
- MYGN 0.50
- MACD
- KBDC 0.00
- MYGN -0.22
- Stochastic Oscillator
- KBDC 0.00
- MYGN 1.28
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.